Benitec Biopharma Reports Durable BB-301 Responses at 24 Months and $184.8M Cash
BNTC•Benitec Biopharma reported durable 12- and 24-month responses to low dose BB-301 and further improvements at 3 months for high dose in its Phase 1b/2a OPMD study, with no treatment-related severe adverse events observed. The company holds $184.8 million in cash to fund BB-301 pivotal study design and 2H-2026 interim updates.
1. Clinical Study Progress
Benitec has completed enrollment of six patients in Cohort 1 and treated two patients in Cohort 2 of its Phase 1b/2a BB-301 trial for OPMD-related dysphagia. Low dose BB-301 showed sustained clinical responses at 12 and 24 months, while high dose patients demonstrated further depth of response at the 3-month follow-up with no severe adverse events reported.
2. Financial Results
For the quarter ended March 31, 2026, total expenses were $13.6 million, down from $15.3 million a year earlier, reflecting stable R&D spending of $6.3 million and reduced G&A costs of $7.3 million. Net loss attributable to shareholders narrowed to $11.9 million, or $(0.24) per share, and cash and equivalents stood at $184.8 million as of quarter end.
3. Upcoming Milestones
Benitec plans to engage the FDA mid-year to finalize the BB-301 pivotal study design and will present interim Phase 1b/2a results at the ASGCT Annual Meeting on May 15. The company expects to report additional interim data for both Cohort 1 and Cohort 2 in the second half of 2026.
